Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
Blood Advances|August 28, 2025
Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND studyAli T Taher, Vip Viprakasit, Antonis Kattamis, et al.
Haematologica|December 3, 2009
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasMaria Domenica Cappellini, John Porter, Amal El-Beshlawy, et al.
European Journal of Haematology|April 24, 2023
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspaterceptMaria Domenica Cappellini, Ali T Taher, Antonio Piga, et al.
The Lancet. Haematology|February 13, 2025
Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trialMaria Domenica Cappellini, Vip Viprakasit, Pencho Georgiev, et al.
Cell|October 30, 2010
ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent mannerMartin J Law, Karen M Lower, Hsiao P J Voon, et al.
British Journal of Haematology|January 16, 2016
The genetic basis of asymptomatic codon 8 frame-shift (HBB:c25_26delAA) β(0) -thalassaemia homozygotesZhihua Jiang, Hong-Yuan Luo, Shengwen Huang, et al.
The Lancet. Haematology|August 25, 2022
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trialAli T Taher, Maria Domenica Cappellini, Antonis Kattamis, et al.
Blood|April 4, 2009
Iron overload in the Asian communityChun Yu Lok, Alison T Merryweather-Clarke, Vip Viprakasit, et al.
Scientific Reports|December 27, 2024
Pharmacogenomic landscape of the Thai population from genome sequencing of 949 individualsJittima Piriyapongsa, Supatat Chumnumwat, Pavita Kaewprommal, et al.
Lancet (London, England)|June 22, 2025
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trialAli T Taher, Hanny Al-Samkari, Yesim Aydinok, et al.
Pageof 16